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THE identification of cancer cells in the circulating blood and the thoracic
duct lymph implicates both of these systems as potential routes for cancer dis-
semination. In 1798, Astley Cooper first described involvement of the thoracic
duct by malignant disease. Virchow's observation in 1849 of left supraclavicular
lymph node metastases associated with abdominal cancer indicated spread by way
of the thoracic duct. Stevens, in 1907, pointed out that the thoracic duct plays
an important role in the dissemination of intra-abdominal malignant disease,
either by being directly involved by tumour or by acting as a " simple carrier "
of tumour emboli. In recent years, such investigators as Young (1956) and Celis,
Kuthy and del Castillo (1956) have shown that the thoracic duct is frequently
involved by malignant disease; and in 1960, Watne, Hatiboglu and Moore were
able to identify free tumour cells in the thoracic duct lymph. The relative im-
portance of the role of the thoracic duct as a conduit for cancer dissemination to
the lungs and other organs is still unknown, however. The following investiga-
tions were designed to shed some light on this phenomenon.
CLINICAL OBSERVATIONS
Methods
Thoracic duct cannulation was carried out in 98 patients with advanced
malignant disease, using a technique described previously (Watne, Hatiboglu and
Moore, 1960). Cytological preparations by means of the Papanicolaou preserva-
tion and staining technique were made on aliquots of the daily lymph flow, and
were screened for malignant cells. Leucocytes and cancer cells were isolated from
10 ml. antecubital vein blood samples, using the modified streptolysin 0 technique
described by Long and his associates (1959). Clinical and autopsy records were
obtained from our hospital records.
Results and discussion
Cancer cells were idenitified in the lymph of 16 of the 98 patients. Typical
examples of such cells are shown in Fig. 1. Cancer cells were identified in the
peripheral blood in 4 out of 59 patients examined, and all 4 of these patients also
had tumour cells identified in the thoracic duct lymph.
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TABLE I. Metastases and Cancer Cells in the Thoracic Duct Lymph and
Peripheral Blood in 98 Patients with Advanced Cancer
Peripheral
blood Pulmonary Hepatic
Thoracic duct Numnber metastases metastases
lymph of Nega- Not
examination patients Positive tive examined Present Absent Present Absent
Positive for cancei cells 16 4 12 - 7 9 2 14
Negative for cancer cells 82 0 43 39 31 51 . 26 56
Total 98 4 55 39 . 38 60 28 70
Table I gives a summary of the occurrence of tumour cells in the lymph and
peripheral blood, together with the associated metastases. Of 38 patients with
lung metastases, none had tumour cells in the blood, but 7 had tumour cells in the
thoracic duct lymph. Six of these patients had, respectively, carcinomas of the
lung, bladder, breast, common bile duct, testis and rectum, and the seventh had
a malignant melanoma of the eye. Liver metastases occurred in 28 of the 98
patients. Tumour cells were identified in the lymph in a patient with liver meta-
stases from carcinoma of the breast, and in both the lymph and the peripheral
blood in a patient with liver metastases from cancer of the stomach. Lung meta-
stases also occurred in 8 of these 28 patients. It is interesting that the other 3
patients in whom tumour cells were identified in both lymph and peripheral blood
had extensive local disease, but no evidence of distant metastases.
Pulmonary metastases often became evident clinically some months after
the thoracic duct had been examined for the presence of tumour cells. Such
delayed metastases occurred in 13 out of 31 patients with negative lymph examina-
tions, and in 4 out of 7 patients whose lymph examinations were positive.
Further evidence that the existence of pulmonary metastases is perhaps more
common in malignant disease than is generally thought is shown by a review of
693 patients treated for colorectal cancer in our Institute during the years 1950
to 1959 inclusive. Two years or more after treatment, only 220 were still alive,
whereas 473 had died-the great majority from their malignant disease. Autopsy
examination was carried out in 181 of the latter group, and pulmonary metastases
were present in 54 (30 per cent).
All but 3 of these 54 patients had had a chest X-ray within six months of
death. In 28 patients there was definite radiological evidence of pulmonarv
metastases, and in 7 the presence of metastases was suspected. In the remaining
19 patients, however, the pulmonary metastases were not suspected before death,
anid were diagnosed only at autopsy. In 6 of these, the foci in the lungs were
described as being " microscopic ". Thus there may be an appreciable time lag
between the actual inception of pulmonary metastases and their clinical recogni-
tion, and this may account for some of the findings in the present investigation.
LABORATORY OBSERVATIONS
In order to assess further the significance of tumour cells in the thoracic duct
lymph stream, varying numbers of viable malignant cells were inoculated directly
into the cisterna chyli in a series of isogenetic adult CFN Wistar Albino rats
(obtained from Carworth Farms, New York, New York). The animals weighed
175 to 200 g. at the time of inoculation, and were kept under standard conditions,
being maintained on Purina chow pellets and tap water ad libitumn.
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Methods
Cells of Walker 256 carcinosarcoma (propagated as an ascites tumour in rats
isogenetic to the experimental group) were suspended in tissue culture medium
199. The viable cells in the inoculant were counted by the nigrosin differential
staining method described by Kaltenbach, Kaltenbach and Lyons, (1958).
The recipient animals were divided into four groups of 72 animals each. The
first group received 1,000,000 viable cells apiece, the second group 100,000, the
third group 10,000, and the fourth group 1000. The subdiaphragmatic cisterna
chyli (Fig. 2) was exposed under light ether anaesthesia according to the method
described by Boilman, Cain and Grindlay (1948). With gentle blunt dissection,
the vessel becomes readily accessible over a length of 10 to 15 mm. The cisterna
chyli is most easily identified when filled with milky chyle, and for this reason
inoculations were made during the morning, when the intestinal lymphatics appear
to be in greatest use.
An " angled " No. 30 gauge needle was used for the inoculation, and concentra-
tions of cells were prepared so that the volume inoculated never exceeded 0-2 ml.,
in order to prevent over-distension of the fragile lymph sac. The needle was held
in position for 30 seconds after the injection, to allow the flow oflymph to take the
suspension of cells upwards. It was hoped that this would minimize the risk of
back-leakage and contamination of the local tissues.
The course of the duct was demonstrated by a preliminary experiment in
which Brilliant Green dye was injected into the cisterna chyli. The dye was
observed to pass through the thoracic duct and to empty into the mediastinal
veins, with some residual stain persisting on the walls of the duct. Some flow of
dye was noted to proceed both into the cervical lymphatics and into minute
lymphatic communications, with resultant staining of intrathoracic and cervical
lymph nodes. Lymphatic connections between the thoracic duct and adjacent
lymph nodes have been described previously by Zeidman (1955) and by Celis and
his colleagues (1956). It was anticipated that the inoculated cancer cell suspen-
sion would follow the same pathway as was illustrated by these dye studies.
The animals in each group were randomly allotted to three subgroups. Those
in subgroup A were killed 18 days after inoculation. The animals in subgroup B
were to have been killed 42 days after inoculation, but actually the majority of
animals with tumours succumbed before this time limit. The animals in subgroup
C were subjected to the stress of laparotomy under light ether anaesthesia on the
the 18th day, and were killed 42 days after inoculation ifsurviving until that time.
A number ofanimals died from unrelated causes during the first week afterinocula-
tion. These were excluded from the series.
EXPLANATION OF PLATES
FIG. 1.-Tumour cells from the thoracic duct lymph. Carcinoma of the stomach.
FIG. 2.-Dissection of the rat to show the cisterna chyli (arrowed) in the retroperitoneal tissues.
FIG. 3.-Pulmonary implantation metastases.
FIG. 4.-Histological section of pulmonary implantation metastasis.
FIG. 5.-Mediastinal tumour in the region of the thymus.
FIG. 6.-Hepatic implantation metastases.
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Results and discussion
The results in terms of overt tumour development are shown in Table II.
Despite the precautions taken, subdiaphragmatic local tumours, varying from a
small nodule to a large mass, developed at the site ofinoculation in 84 of the 247
animals. In Table III, such animals with local tumours have been excluded,
although comparison of Tables II and III suggests that in this particular system
TABLE II.-Distribution ofOvert Tumour in Adult Wistar Rats
































TABLE III.-Distribution of Overt Tumour After Excluding all Animals







in group Number Total
31 . 17 55
37 . 9 24*5
42 . 11 24
53 . 11 21
























the presence of such a local tumour does not significantly affect the incidence of
pulmonary and other intrathoracic metastases. It might be mentioned here that
we never observed pulmonary or hepatic metastases in any of the donor animals
used to propagate the ascites tumour throughout the course of the experiment.
Pulmonary implant metastases occurred with considerable frequency, and in
the majority of cases both lungs were involved. Many intrathoracic tumours
were produced-either in association with pulmonary lesions, or as solitary meta-
static masses. In many instances, the masses occupied the upper mediastinal
and thymic regions; in others, scattered deposits occurred over the parietal
pleura. The distribution of these deposits is in accord with the results obtained
by Zeidman (1955) in a similar experiment. Although subdiaphragmatic tumour
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that this acted as a source for intrathoracic lesions. Fig. 3 and 4 illustrate pul-
monary metastases, and in Fig. 5 a tumour mass is shown occupying the regionl of
the thymus.
The pulmonary metastasis "dose-response " relationship shows a quantita-
tive correlation, which is similar in some respects to that observed in the liverafter
the intraportal inoculation of tumour cells into groups of Wistar rats under con-
ditions identical to those in the lymphatic series (Table IV). A quantitative
intraportal "dose-response " relationship has also been observed by other in-
vestigators (Fisher and Fisher, 1959a; Koike, Nakazato and Moore, 1962). It
would seem, however, that the liver of the adult Wistar rat is more capable of
resisting the insult of direct inoculation ofrelativelv small numbers of cells thani are
the lungs (Table IV).
TABLEIV.-Compari8on of Overt Pulmonary and Hepatic Implantation Metastas,es
Incidence of pulmonary Incidence of hepatic
implantation metastases implantation metastases
after cisternal inoculation after portal vein inoculation
Number of Number of
Number of animals % Number of animals %
Number animals with with animals with with
of cells in group metastases metastases in group metastasesmetastase.
106 64 36 56 66 35 53
105 62 24 39 62 21 34
104 59 16 27 69 9 13-5
103 62 14 22-5 67 2 3
Total . 247 90 37 264 67 25-5
In the majority of rats (68 out of 90), the pulmonary deposits included more
than 20 implant metastases counted. Occasionally a solitary large deposit was
evident in a lung which otherwise appeared normal macroscopically.
A smaller percentage ofthe animals which were killed 18 days afterinoculation
(subgroup A) had obvious pulmonary implant metastases than did those allowed
to survive thelongerperiod of42 days (subgroup B)-namely 26 per cent as against
40O5per cent (Table V). Ofthe animals with pulmonary involvement in subgroup
A, fewer showed multiple implant metastases (as defined above) than did those
in subgroup B, and, as might be expected, the lesions were smaller.
In 3 of the animals in subgroup A, unsuspected pulmonary deposits were
identified microscopically. It may therefore be assumed that had all the rats
been allowed to survive their natural span, the total number with overtpulmonary
implant metastases would have been even greater than that recorded here.
The role of" stress " in decreasing the resistance of animals to cancer cell ino-
culation has aroused considerable interest in recent years (Buinauskas, McDonald
and Cole, 1958; Fisher and Fisher, 1959b). Should such a mechanism apply in
human cancer, it would obviously have considerable clinical implications. In
the present animal investigation, however, the stress of laparotomy had no sigIni-
ficant effect upon the incidence of pulmonary deposits, comparable results being
obtained in the B and C subgroups at all cell concentrations (Table V).
Hepatic implant metastases occurred in 12 of the 247 rats inoculated via the
cisterna chyli (Fig. 6), and this incidence is interesting. In all cases, there were
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TABLE V.-Incidence of Overt Pulmonary Implantation Metastases Related
to the Time of Termination and the Stress of Interval Laparotomy
SUBGROUP C
SUBGROUP B Interval laparotomy
SUBGROUP A Killed at 42 days at 18 days.
Killed at 18 days if still surviving Killed at 42 days,
if still surviving
Number Number % with Number % with Number %with
of of pulmonary of pulmonary of pulmonary
cells animals metastases animals metastases animals metastases
106 21 38 22 68 21 62
105 20 40 20 35 22 41
104 19 16 20 30 20 35
103 20 10 19 26-5 23 30 5
Total 80 26 81 40 5 . 86 42
co-existent pulmonary or intrathoracic metastases. The mode of origin of these
hepatic implant metastases is open to conjecture, and at least three different
explanations are possible.
In the first place, 7 of the animals with hepatic deposits had a local tumour
at the site ofinoculation, and it is possible that this served as the source. In our
opinion this is unlikely, however, as previous experience with the Walker 256
carcino-sarcoma in this laboratory suggests that it has little natural metastasizing
ability.
A second conceivable explanation is that tumour cellsreached the liverthrough
the systemic circulation in numbers sufficient to permit the development of intra-
hepatic tumour masses. The release of inoculated tumour cells from the pul-
monary bed into the systemic circulation has been demonstrated in other tumour
systems by Ambrus and his colleagues (1956), who were able to demonstrate large
numbers of both pulmonary and hepatic metastases after tail vein inoculation of
various mouse strains with 2 X 107 Ehrlich ascites tumour cells. This has not
been the experience of other investigators, however, when smaller numbers of
cells have been inoculated. Koike (1962, personal communication), for example,
has been unable to demonstrate hepatic metastases after tail vein inoculation ofup
to 5 x 106 Ehrlich (hyperdiploid) ascites tumour cells in normal mice. In any
event, what is true of one tumour system is not necessarily true of another, and
no definite decision in regard to this second explanation is possible without further
investigation.
A third possible explanation is that the spread to the liver was in fact lympha-
tic in origin. It may have occurred either as the result of direct communications
between intrathoracic and subdiaphragmatic lymphatics, or as a result of obstruc-
tion to the thoracic duct and the passage of tumour cell emboli through resultant
collateral lymphatic pathways, or by retrograde passage through abdominal
lymphatics. The existence of a collateral circulation in cases of duct obstruction
has been commented upon by Celis and his associates (1956). That obstruction
to the thoracic duct occurred in many of the animals in the present study was
suggested both by the presence oflarge intrathoracic masses in the line ofthe duct.
and by the absence of success in outlining the duct in such animals upon the injec-
tion of Brilliant Green dye into the intestinal lymphatics. The possibility also
has to be considered that tumour growth occurred within the thoracic duct by
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direct implantation, thus causing its obstruction by a ready source of subsequent
tumour emboli.
COMMENT
In the particular system used in the animal experiment, it is clear that pul-
monary tumours occur with considerable frequency following the injection of
tumour cells into the cisterna chyli. The facility with which metastases are
produced bears a direct relationship to the number of free-floating viable cells
which are present, and is unlikely to be affected by stress factors.
As a result of thoracic duct communications, tumour implantation masses
also occur in the intrathoracic and cervical node groups. A significant number
of hepatic metastases develop after direct inoculation of the cisterna chyli with
viable tumour cells. The derivation of such hepatic metastases is open to con-
jecture, and is the subject of a further investigative study now being undertaken.
In human cancer, the free-floating tumour cell can be demonstrated in the
thoracic ductlymph-associated with a variety oflesions. These cellspresumably
escape the lymph node " barrier " action referred to by Gilchrist (1940) and by
Zeidman and Buss (1954), either as a result of direct lymphatic communications
which by-pass lymph node groups, or as the result of complete overwhelming of
the barrier. Such cells may lodge in the lung, and it is likely that the greater the
number of tumour cells within the thoracic duct lymph, the greater is the chance
ofmetastasis formation within the lung. Clinically, occult pulmonary metastases
are probably much more common in malignant disease than they are generally
thought to be.
We feel certain that the thoracic duct does act as a conduit for large numbers
of tumour cells, in man, especially in patients with advanced malignant disease.
It is reasonable to assume, therefore, that metastases in the lungs are just as
likely to result from this mode of spread as from spread by other more direct
vascular routes.
SUMMARY
1. Examination of the thoracic duct lymph in 98 patients with malignant
disease was positive for tumour cells in 16. Of 38 patients with pulmonary
metastases, 7 had tumour cells identified in the thoracic duct lymph. In 4 of
these 7 patients, thelung metastases became obvious afterthelymph examination.
It is apparent from the results of autopsy studies in a group of 181 patients who
diedfrom colorectal cancerthattheincidence ofpulmonarymetastasesinadvanced
malignant disease is higher than is suggested on clinical and radiological
examination.
2. In an experimental animal system in which malignant cells were inoculated
directly into the cisterna chyli, an appreciable rate of pulmonary malignancy
ensued, and a quantitative " dose-response " relationship was established.
3. The thoracic duct lymph is an important vehicle in the dissemination of
malignant tumour cells, and must be regarded as a potential source ofpulmonary
metastases.
Supported in part by United States Public Health Service research grant
CY 4723.
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